Cognition Therapeutics, Inc. - Common Stock — Cash Flow (NASDAQ:CGTX) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -3.63 M-18.53 M-16.02 M-28.47 M-24.59 M -20.25 M Cash from investing activities -27 K-171 K-147 K-4 0009 000 — Cash from financing activities 53.2 M5.55 M4.52 M23.57 M36.57 M 35.04 M Free cash flow -3.63 M-18.53 M-16.02 M-28.47 M-24.59 M -20.25 M

News

Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript

Cognition presents data on dementia drug zervimesine at conference

Cognition Therapeutics shifts focus to DLB psychosis treatment

Cognition Therapeutics holds FDA meeting on Lewy bodies dementia drug

Cognition’s DLB drug shows positive results in phase 2 trial

Cognition Therapeutics completes enrollment in expanded access program

Cognition Therapeutics outlines Phase 3 plans for Alzheimer’s drug

Cognition Therapeutics: A High-Stakes Bet On A Single Drug - Why I Hold (NASDAQ:CGTX)

Cognition Therapeutics completes enrollment in Alzheimer’s drug trial

Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?

Cognition Therapeutics (CGTX) Moves to Buy: Rationale Behind the Upgrade

Cognition’s Alzheimer’s drug trial reaches 75% enrollment milestone